MTOR and hepatocellular carcinoma: The largest randomized controlled trial for the clinical effect of mTOR inhibitor in LT recipients for HCC recently showed mTOR inhibitor used for more than 3 months significantly reduced overall survival [27], although it failed to show a preventive effect for HCC recurrence in its initial analyses [28].